BACKGROUND: A stomach-preserving duodenal-jejunal bypass (DJB) has been used for the treatment of type 2 diabetes mellitus (DM) since Rubino et al. first reported a prospective trial. However, there has been no report on changes in incretin secretion after DJB. We aimed to investigate whether DJB changes incretin secretion in nonmorbidly obese type 2 diabetic patients. METHODS: The inclusion criteria in this prospective study were: patient age of 20-65 years, body mass index of <30 kg/m(2), a history of type 2 DM for ≤10 years, and fasting C-peptide ≥0.3 nmol/l. Six patients with type 2 DM without morbid obesity underwent DJB. Fasting plasma glucose and glycated hemoglobin (HbA1c) were measured. An oral glucose tolerance test (OGTT) was performed with measurement of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), insulin, C-peptide, and glucagon. The study subjects were followed up for 6 months. RESULTS: The body weight of patients declined after surgery. The area under the curve (AUC) of glucose, peak glucose levels during OGTT, and HbA1c also declined until 3 months postoperatively. The AUC of C-peptide and insulin tended to increase postoperatively. The AUC of glucagon had a significant increase at 6 months postoperatively. The AUC of active GLP-1 increased at 1 month and at 6 months postoperatively. There was no change in the AUC of total GIP. CONCLUSION: Our data suggest that DJB increases GLP-1 secretion in nonmorbidly obese type 2 diabetic patients. However, long-term data are needed to confirm this finding.
BACKGROUND: A stomach-preserving duodenal-jejunal bypass (DJB) has been used for the treatment of type 2 diabetes mellitus (DM) since Rubino et al. first reported a prospective trial. However, there has been no report on changes in incretin secretion after DJB. We aimed to investigate whether DJB changes incretin secretion in nonmorbidly obese type 2 diabeticpatients. METHODS: The inclusion criteria in this prospective study were: patient age of 20-65 years, body mass index of <30 kg/m(2), a history of type 2 DM for ≤10 years, and fasting C-peptide ≥0.3 nmol/l. Six patients with type 2 DM without morbid obesity underwent DJB. Fasting plasma glucose and glycated hemoglobin (HbA1c) were measured. An oral glucose tolerance test (OGTT) was performed with measurement of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), insulin, C-peptide, and glucagon. The study subjects were followed up for 6 months. RESULTS: The body weight of patients declined after surgery. The area under the curve (AUC) of glucose, peak glucose levels during OGTT, and HbA1c also declined until 3 months postoperatively. The AUC of C-peptide and insulin tended to increase postoperatively. The AUC of glucagon had a significant increase at 6 months postoperatively. The AUC of active GLP-1 increased at 1 month and at 6 months postoperatively. There was no change in the AUC of total GIP. CONCLUSION: Our data suggest that DJB increases GLP-1 secretion in nonmorbidly obese type 2 diabeticpatients. However, long-term data are needed to confirm this finding.
Authors: Ricardo V Cohen; Carlos A Schiavon; José S Pinheiro; Jose Luiz Correa; Francesco Rubino Journal: Surg Obes Relat Dis Date: 2007 Mar-Apr Impact factor: 4.734
Authors: Francesco Rubino; Antonello Forgione; David E Cummings; Michel Vix; Donatella Gnuli; Geltrude Mingrone; Marco Castagneto; Jacques Marescaux Journal: Ann Surg Date: 2006-11 Impact factor: 12.969
Authors: G Mingrone; A DeGaetano; A V Greco; E Capristo; G Benedetti; M Castagneto; G Gasbarrini Journal: Diabetologia Date: 1997-05 Impact factor: 10.122
Authors: B Detournay; S Cros; B Charbonnel; A Grimaldi; F Liard; J Cogneau; F Fagnani; E Eschwège Journal: Diabetes Metab Date: 2000-11 Impact factor: 6.041
Authors: C Dirksen; N B Jørgensen; K N Bojsen-Møller; S H Jacobsen; D L Hansen; D Worm; J J Holst; S Madsbad Journal: Diabetologia Date: 2012-04-27 Impact factor: 10.122
Authors: John B Dixon; Nora E Straznicky; Elisabeth A Lambert; Markus P Schlaich; Gavin W Lambert Journal: Nat Rev Gastroenterol Hepatol Date: 2011-07-05 Impact factor: 46.802
Authors: Samuel Klein; Elisa Fabbrini; Bruce W Patterson; Kenneth S Polonsky; Carlos A Schiavon; Jose L Correa; Joao E Salles; Bernardo L Wajchenberg; Ricardo Cohen Journal: Obesity (Silver Spring) Date: 2012-01-19 Impact factor: 5.002
Authors: Troy H Dillard; Jonathan Q Purnell; Mark D Smith; William Raum; Dennis Hong; Jamie Laut; Emma J Patterson Journal: Surg Obes Relat Dis Date: 2011-10-19 Impact factor: 4.734
Authors: Clémence D Côté; Melika Zadeh-Tahmasebi; Brittany A Rasmussen; Frank A Duca; Tony K T Lam Journal: J Biol Chem Date: 2014-02-27 Impact factor: 5.157